Last reviewed: May 23, 2026

Last updated: May 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, recent clinical evidence suggests semaglutide may help reduce cardiovascular events in patients with type 2 diabetes and established heart disease. The SUSTAIN-6 trial (published in 2016) showed a 26% reduction in major adverse cardiovascular events in semaglutide-treated patients compared to placebo.

For individuals considering GLP-1 therapy, understanding your metabolic baseline and genetic predispositions to peptide pathway responsiveness can help inform a provider conversation about whether this treatment aligns with your cardiovascular health goals. PlexusDx takes a precision approach by integrating biomarker context with medication options.

Cardiovascular Benefits in Clinical Trials: What the Evidence Shows

Multiple large-scale randomized controlled trials have examined semaglutide's cardiovascular safety and efficacy. The SUSTAIN-6 trial enrolled over 3,000 patients with type 2 diabetes and found semaglutide reduced the composite endpoint of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

Subsequent trials, including LEADER (liraglutide) and HARMONY (albiglutide), strengthened the evidence that GLP-1 agonists reduce cardiovascular risk. However, benefits vary across patient populations, and individual baseline health status significantly influences treatment response and outcomes.

Cardiovascular Risk Factors and Biomarker Assessment: A Personalization Framework

Before starting semaglutide or tirzepatide, providers often evaluate key biomarkers reflecting cardiovascular risk: fasting glucose, HbA1c, lipid profiles, blood pressure, inflammatory markers (like CRP), and kidney function. These baseline measurements help establish whether GLP-1 therapy fits your individual cardiovascular risk profile and treatment goals.

Biomarker / Risk Factor Clinical Significance for GLP-1 Therapy
HbA1c (glycated hemoglobin) Primary glycemic control measure; GLP-1s typically reduce by 1.0–1.8%; higher baseline = greater absolute reduction potential
LDL and HDL cholesterol GLP-1 therapy may improve lipid ratios; supports cardiovascular risk reduction alongside weight loss
Blood pressure Modest BP reduction observed with GLP-1s; relevant for hypertension co-management in cardiac patients
eGFR (kidney function) Critical safety parameter; GLP-1s are generally safe in CKD but require baseline assessment; inform dosing and monitoring

Genetic Pathway Predispositions and Treatment Response Variability

Individual genetic variation in GLP-1 receptor signaling, GIPR sensitivity, and metabolic pathways (FTO, MC4R) may influence how your body responds to semaglutide or tirzepatide. While genetics do not determine exact medication response, they can provide context about pathway engagement and metabolic flexibility.

PlexusDx's Precision Peptide Genetic Test examines key variants in peptide signaling pathways (GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, MC4R rs17782313) to help you and your provider understand your genetic predispositions in these metabolic networks. This insight may support more informed discussions about dose optimization and adjunctive strategies.

Safety Considerations and Provider Guidance: Who Benefits Most

Semaglutide is FDA-approved for glycemic control in type 2 diabetes and weight management; cardiovascular benefits are observed primarily in patients with established diabetes and prior cardiovascular disease. Patients with a history of medullary thyroid cancer, MEN2 syndrome, or severe gastrointestinal disease require careful provider evaluation before use.

A qualified healthcare provider should assess your complete medical history, current medications, kidney function, and cardiovascular status before initiation. Regular monitoring of blood glucose, blood pressure, and metabolic markers ensures safety and identifies any need for dose adjustment or complementary interventions aligned with your cardiovascular goals.

How PlexusDx Supports a More Personalized Approach

PlexusDx genetic and biomarker assessments may help provide context about your individual peptide pathway engagement and baseline cardiovascular risk profile. The Precision Peptide Genetic Test reveals predispositions in GLP-1 receptor signaling and metabolic pathways that can support a more personalized conversation with your provider about whether GLP-1 therapy fits your health goals.

The genetic test examines four key variants (GIPR, GLP1R, FTO, MC4R) implicated in peptide response and weight regulation. These predispositions should be interpreted with a qualified healthcare provider; they do not predict exact medication response or guarantee cardiovascular outcomes, but they contextualize your individual pathway strengths and potential engagement with GLP-1 therapy.

Understanding your genetic and biomarker baseline allows you to approach GLP-1 treatment decisions with greater clarity. PlexusDx compounded semaglutide ($149/mo) and tirzepatide ($249/mo) from licensed 503A pharmacies offer accessible alternatives while your provider evaluates how these therapies align with your cardiovascular health strategy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Related Reading

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves